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Backgrounds:	 Acotiamide	 is	 a	 novel	 acetylcholinesterase	 inhibitor	 for	 treatment	 of	
postprandial	distress	syndrome	(PDS)	symptoms	of	functional	dyspepsia	(FD).
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1  | INTRODUCTION




clinical	 evaluation.	 The	 global	 prevalence	 rate	 of	 FD	 is	 reported	 to	
range	between	5%	and	11%	when	using	 the	ROME	 III	 criteria.3	FD	
encompasses	two	subgroups	in	both	ROME	III	and	ROME	IV	criteria,	
namely	the	Postprandial	distress	syndrome	(PDS),	which	is	character-




The	quality	of	 life	 (QoL)	 in	FD	patients	 is	known	to	be	 impaired	
due	to	symptoms	causing	emotional	distress,	problems	with	food	and	
drink,	and	impaired	vitality.4
Furthermore,	 FD	 produces	 a	 considerable	 economic	 impact	 on	
both	direct	 and	 indirect	 cost.	 In	 a	 retrospective	 study	 conducted	 in	
USA,	the	adjusted	mean	annual	cost	for	employees	with	FD	was	more	
























2  | MATERIALS AND METHODS
2.1 | Trial design




and conducted in accordance with the ethical principles originating in 
the	Declaration	of	Helsinki,	and	are	consistent	with	the	International	
Council	for	Harmonization	Good	Clinical	Practice	guidelines,	applicable	











able	 to	 discontinue	 drugs	 affecting	 gut	 motility,	 sensitivity	 and/or	
acid	secretion;	without	predominant	symptoms	of	irritable	bowel	syn-
drome,	gastroesophageal	reflux	disease	or	chronic	idiopathic	nausea.	
Female	patients	of	childbearing	potential	were	 required	 to	agree	 to	













concomitant	 medication,	 body	 weight/height,	 and	 pregnancy	 was	
Key Points
•	 Functional	 dyspepsia	 is	 defined	 as	 unexplained	 upper	
gastrointestinal	 symptoms.	 It	 is	 highly	 prevalent	world-
wide	 and	 produces	 a	 considerable	 economic	 impact,	




•	 This	result	would	provide	additional	 input	 in	the	clinical	
data	accumulated	for	acotiamide	in	Europe,	a	novel	treat-
ment that would meet the unmet clinical need against 
Functional	dyspepsia.






The	 primary	 objective	 of	 this	 trial	 was	 to	 confirm	 the	 long-	term	
safety	of	100	mg	acotiamide	three	times	daily.	By	this	means,	adverse	
events,	ECGs,	laboratory	variables,	vital	signs,	and	physical	examina-
tion results were recorded throughout the trial.
2.3.3 | Efficacy outcomes



























impairment	 was	 assessed	 by	 an	 11-	point	 Likert	 scale,	 with	 higher	







Two	analysis	 sets	were	defined	 in	 this	 trial:	 a	 safety	analysis	 set	






Between	 March	 2014	 and	 September	 2015,	 354	 patients	 were	
screened,	297	patients	proceeded	to	the	run-	in	period,	and	207	pa-
tients	were	enrolled	 (Figure	2).	Among	the	enrolled	population,	185	
patients	 (89.4%)	 completed	 12	weeks,	 175	 patients	 (84.5%)	 com-
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treatment.	All	enrolled	patients	were	included	in	both	Safety	and	Full	
analysis sets.
Patient	 demographics	 are	 shown	 in	Table	1.	The	majority	 of	 the	













A	 total	 of	 18	 (8.7%)	 patients	 reported	 at	 least	 one	 treatment-	
related	 TEAE,	 and	 events	 that	 were	 reported	 in	 ≥1%	 of	 the	 total	
population	were	nausea	(1.4%),	abdominal	distension	(1.0%),	and	con-
stipation	(1.0%).
Four	patients	 experienced	 severe	TEAEs	 (feces	discolored,	 ileus,	









tritis,	 decreased	 appetite,	 and	 dysgeusia.	 One	 patient	 discontinued	
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problems”	 showed	 an	 increase	 (improvement)	 over	 the	 minimally	













time	missed)	 remained	stable	during	 the	52	week	 treatment	period,	




Following	 the	 market	 withdrawal	 of	 cisapride	 and	 the	 restriction	
against	domperidone	and	metoclopramide,	there	is	no	evidence-	based	
medication	in	Europe	for	a	safe	long-	term	usage	against	meal-	related	
symptoms	 of	 FD.	Multiple	 treatments2,20 and management strategy 
schemes21	have	been	suggested,	however,	it	is	of	note	that	treatments	
such	as	empirical	use	of	proton-	pump	inhibitors	are	given	to	a	 large	
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number	of	patients	 and	 there	 is	 an	unmet	need	 for	evidence-	based	
treatment	to	be	given.	There	have	been	multiple	attempts	of	establish-
ing	an	effective	treatment	for	meal-	related	symptoms,	however,	many	
have	 resulted	 in	 disappointment,	 including	 the	 antidepressants	 ami-











Mean T- score (mean change from baseline)
Baseline Week 12 Week 26 Week 38 Week 52
N = 207 N = 185 N = 175 N = 170 N = 168
Physical component 2 50.1 53.7	(3.4) 55.0	(4.5) 55.0	(4.4) 55.6	(5.2)
Mental	component 3 44.4 48.8	(4.2) 50.8	(6.5) 50.7	(6.1) 52.0	(7.6)
Physical	functioning 3 50.7 54.1	(3.3) 54.9	(3.9) 55.3	(4.3) 55.8	(4.9)
Role limitations due to physical 
health problems
3 47.1 51.1	(3.8) 53.2	(6.0) 52.5	(5.1) 53.9	(6.9)
Bodily	pain 3 52.7 55.8	(2.7) 57.4	(4.0) 56.8	(3.3) 57.9	(4.6)
General	health 2 41.5 47.2	(5.3) 48.9	(7.1) 49.4	(7.6) 49.7	(7.9)
Vitality 2 50.1 54.5	(4.1) 56.2	(5.7) 56.7	(6.0) 57.7	(7.1)
Social	functioning 3 45.7 50.6	(4.7) 52.6	(6.9) 52.1	(6.2) 52.9	(7.1)
Role limitations due to emotional 
problems
4 44.9 48.6	(3.3) 51.8	(6.7) 50.9	(5.5) 52.1	(7.1)
General	mental	health 3 45.2 49.7	(4.3) 50.3	(5.2) 50.6	(5.4) 52.1	(7.2)
The	mean	change	has	been	calculated	for	patients	with	data	for	both	baseline	and	each	timepoint.
MID,	Minimally	important	difference.
     |  7 of 8TACK eT Al.
administered	 for	 a	 long-	term.	 Such	 findings	 align	with	 the	 result	 of	





















major	 limitation	of	 this	 trial	 is	 the	open-	label	design,	 as	a	high	placebo	
effect	 is	commonly	observed	 in	clinical	 trials	for	Functional	gastrointes-





the	 two	cardinal	meal-	related	 symptoms	 (PPF	and	early	 satiation)	both	








and without major overlapping symptoms or diseases such as epigas-











this result would provide additional input in the clinical data accumulated 




Tomoharu	Miyagawa	 is	 acting	 as	 the	 submission’s	 guarantor.	 Jan	
Tack,	 Juris	 Pokrotnieks,	 Gediminas	 Urbonas,	 Christian	 Banciu,	
Vladimir	 Yakusevich,	 Ivan	 Bunganic,	 Hans	 Törnblom,	 Yaroslav	
Kleban	and	Patrick	Eavis	have	performed	the	research.	Tomoharu	
Miyagawa	 designed	 the	 research	 study	 and	wrote	 the	 paper.	 Jan	
Tack,	Masaru	Tsuchikawa	and	Tomoharu	Miyagawa	contributed	to	
the	design	of	 the	 study.	All	 authors	approved	 the	 final	 version	of	
the manuscript.
DISCLOSURE
Jan	 Tack	 has	 given	 Scientific	 advice	 to	 Abide	 Therapeutics,	
AlfaWassermann,	 Allergan,	 Christian	 Hansen,	 Danone,	 Genfit,	
Ironwood,	 Janssen,	 Kiowa	 Kirin,	 Menarini,	 Mylan,	 Novartis,	
Nutricia,	Ono	Pharma,	Rhythm,	 Shionogi,	 Shire,	 SK	 Life	 Sciences,	
Takeda,	 Theravance,	 Tsumura,	 Yuhan,	 Zealand	 and	 Zeria	 phar-
maceutical,	 has	 received	 Research	 grant	 or	 support	 from	 Abide	
Therapeutics,	Shire,	Tsumura,	Zeria	and	has	served	on	the	Speaker	
bureau	 for	 Abbott,	 Allergan,	 AstraZeneca,	 Janssen,	 Kiowa	 Kirin,	
Menarini,	 Mylan,	 Novartis,	 Shire,	 Takeda	 and	 Zeria.	 Gediminas	
Urbonas	 served	 as	 a	 speaker	 for	 Amgen,	 Bayer,	 MSD,	 Servier,	
Sanofi,	AstraZeneca,	 a	 consultant	 and	an	advisory	board	member	
for	 Sanofi.	Hans	Törnblom	 served	 as	 a	 speaker,	 a	 consultant	 and	
an	advisory	board	member	for	Almirall,	Allergan,	Shire	and	Tillotts.	
Masaru	 Tsuchikawa	 and	 Tomoharu	Miyagawa	 is	 an	 employee	 of	
Zeria	Pharmaceutical.	Juris	Pokrotnieks,	Christian	Banciu,	Vladimir	
Yakusevich,	Ivan	Bunganic,	Yaroslav	Kleban,	and	Patrick	Eavis	de-
clare no competing interests. 
ORCID
J. Tack  http://orcid.org/0000-0002-3206-6704 






	 3.	 Ford	 AC,	 Marwaha	 A,	 Sood	 R,	 Moayyedi	 P.	 Global	 prevalence	 of,	
and	risk	 factors	 for,	uninvestigated	dyspepsia:	a	meta-	analysis.	Gut. 
2015;64:1049-1057.
	 4.	 Halling	 K,	 Kulich	 K,	 Carlsson	 J,	 Wiklund	 I.	 An	 international	 com-
parison	of	 the	burden	of	 illness	 in	patients	with	dyspepsia.	Dig Dis. 
2008;26:264-273.
	 5.	 Brook	 RA,	 Kleinman	 NL,	 Choung	 RS,	Melkonian	AK,	 Smeeding	 JE,	
Talley	NJ.	Functional	dyspepsia	impacts	absenteeism	and	direct	and	
indirect costs. Clin Gastroenterol Hepatol.	2010;8:498-503.
	 6.	 Lacy	BE,	Weiser	KT,	Kennedy	AT,	Crowell	MD,	Talley	NJ.	Functional	
dyspepsia: the economic impact to patients. Aliment Pharmacol Ther. 
2013;38:170-177.
	 7.	 Mahadeva	 S,	 Yadav	 H,	 Everett	 SM,	 Goh	 K-L.	 Economic	 impact	 of	
dyspepsia	 in	 rural	 and	urban	Malaysia:	 a	 population-	based	 study.	 J 
Neurogastroenterol Motil.	2012;18:43-57.
8 of 8  |     TACK eT Al.
	 8.	 Matsuzaki	J,	Suzuki	H,	Togawa	K,	et	al.	Burden	of	impaired	sleep	qual-
ity	 on	 work	 productivity	 in	 functional	 dyspepsia	 [published	 online	
August	 7	 2017].	United European Gastroenterol J. 2017. https://doi.
org/10.1177/2050640617726466
	 9.	 Tack	 J,	 Janssen	 P.	 Acotiamide	 (Z-	338,	 YM443),	 a	 new	 drug	 for	










	13.	 Suzuki	 H.	 The	 application	 of	 the	 ROME	 IV	 criteria	 to	 functional	
esophagogastroduodenal	disorders	in	Asia.	J Neurogastroenterol Motil. 
2017;23:325-333.
	14.	 Tack	J,	Stanghellini	V,	Holtmann	G,	et	al.	Efficacy	and	safety	study	of	






	16.	 Talley	NJ,	Verlinden	M,	Jones	M.	Quality	of	 life	 in	 functional	dys-
pepsia:	 responsiveness	 of	 the	 Nepean	 Dyspepsia	 Index	 and	 de-
velopment	 of	 a	 new	10-	item	 short	 form.	Aliment Pharmacol Ther. 
2001;15:207-216.
	17.	 Reilly	 MC,	 Zbrozek	 A,	 Dukes	 E.	 The	 validity	 and	 reproducibil-





	19.	 Maruish	ME,	ed.	User’s Manual for the SF-36v2 Health Survey (3rd ed.). 
Lincoln,	RI:	QualityMetric	Incorporated;	2011.
	20.	 Talley	NJ.	Functional	dyspepsia:	new	insights	 into	pathogenesis	and	
therapy. Korean J Intern Med.	2016;31:444-456.
	21.	 Camilleri	 M,	 Stanghellini	 V.	 Current	 management	 strategies	 and	
emerging	treatments	for	functional	dyspepsia.	Nat Rev Gastroenterol 
Hepatol.	2013;10:187-194.
	22.	 Talley	NJ,	 Locke	GR,	 Saito	YA,	 et	 al.	 Effect	of	 amitriptyline	 and	es-
citalopram	on	functional	dyspepsia:	a	multicenter,	 randomized	con-
trolled study. Gastroenterology.	2015;149:340-349.
	23.	 Vakil	N,	Laine	L,	Talley	NJ.	Tegaserod	 treatment	 for	dysmotility-	like	
functional	dyspepsia:	results	of	two	randomized,	controlled	trials.	Am 
J Gastroenterol.	2008;103:1906-1919.
	24.	 Talley	NJ,	Tack	J,	Ptak	T,	Gupta	R,	Giguere	M.	 Itopride	 in	functional	
dyspepsia:	results	of	two	phase	III	multicentre,	randomised,	double-	
blind,	placebo-	controlled	trials.	Gut.	2008;57:740-746.
	25.	 Bang	CS,	Kim	JH,	Baik	GH,	 et	 al.	Mosapride	 treatment	 for	 func-
tional	dyspepsia:	a	meta-	analysis.	J Gastroenterol Hepatol. 2015;30: 
28-42.
	26.	 Pinto-Sanchez	MI,	 Yuan	Y,	 Bercik	 P,	Moayyedi	 P.	 Proton	 pump	 in-
hibitors	 for	 functional	 dyspepsia.	 Cochrane Database Syst Rev. 
2017;3:CD011194.
	27.	 Tack	 J,	 Masclee	 A,	 Heading	 R,	 et	 al.	 A	 dose-	ranging,	 placebo-	
controlled,	pilot	 trial	 of	Acotiamide	 in	patients	with	 functional	 dys-
pepsia. Neurogastroenterol Motil.	2009;21:272-280.
	28.	 Matsueda	K,	Hongo	M,	Ushijima	 S,	Akiho	H.	A	 long-	term	 study	 of	
acotiamide	 in	 patients	 with	 functional	 dyspepsia:	 results	 from	 an	
open-	label	 phase	 III	 trial	 in	Japan	on	eficacy,	 safety	 and	pattern	of	
administration. Digestion.	2011;84:261-268.
	29.	 Matsunaga	 Y,	 Tanaka	 T,	 Yoshinaga	 K,	 Ueki	 S,	 Hori	 Y,	 Eta	 R,	 et	 al.	




	30.	 Ford	 AC,	 Moayyedi	 P.	 Meta-	analysis:	 factors	 affecting	 placebo	 re-
sponse rate in the irritable bowel syndrome. Aliment Pharmacol Ther. 
2010;32:144-158.
	31.	 Rasmussen	S,	 Jensen	TH,	Henriksen	SL,	 et	 al.	Overlap	of	 symptoms	
of	 gastroesophageal	 reflux	 disease,	 dyspepsia	 and	 irritable	 bowel	
syndrome in the general population. Scand J Gastroenterol. 2015;50: 
162-169.
	32.	 Kaji	M,	Fujiwara	Y,	 Shiba	M,	 et	 al.	 Prevalence	of	overlaps	between	





	34.	 Choi	 YJ,	 Kim	 N,	 Yoon	 H,	 et	 al.	 Overlap	 between	 irritable	 bowel	
syndrome	 and	 functional	 dyspepsia	 including	 subtype	 analyses.	 J 
Gastroenterol Hepatol;2017;9:1553-1561.
How to cite this article:	Tack	J,	Pokrotnieks	J,	Urbonas	G,	et	al.	
Long-	term	safety	and	efficacy	of	acotiamide	in	functional	
dyspepsia	(postprandial	distress	syndrome)—results	from	the	
European	phase	3	open-	label	safety	trial.	Neurogastroenterol 
Motil. 2018;30:e13284. https://doi.org/10.1111/nmo.13284
